Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gunagratinib in advanced solid tumors with FGF/FGFR gene alterations
NCT05372120Phase 2Unknown
- Sponsor
- InnoCare Pharma
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gunagratinib in solid tumor, head and neck cancer (HNC), sponsored by InnoCare Pharma. Status: unknown.
02
Drugs
gunagratinib
03
Conditions
solid tumorhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05372120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372120.